Hereditary Cancer Panel 57 ACMG 20 HBOC & 865 literature reviewed Genes

Hereditary Cancer Panel 57 – Comprehensive Genetic Testing for Cancer Risk Assessment

The Hereditary Cancer Panel 57 from Lab Tests Dubai is a cutting-edge, next-generation sequencing (NGS) test that analyzes 57 clinically actionable genes linked to inherited cancer syndromes empowering you and your doctor to detect risk early, prevent disease, and protect your family

This advanced panel includes:

• ✅ ACMG 20 Genes – Recommended by the American College of Medical Genetics for reporting incidental findings
• ✅ HBOC (Hereditary Breast and Ovarian Cancer) Genes – Including BRCA1, BRCA2, PALB2, CHEK2, ATM
• ✅ Lynch Syndrome Genes – MLH1, MSH2, MSH6, PMS2, EPCAM
• ✅ Other High-Risk Genes – TP53 (Li-Fraumeni), PTEN (Cowden), APC (FAP), CDH1, STK11, RAD51C/D, and more

It assesses your inherited risk for:

• Breast & Ovarian Cancer
• Colorectal, Endometrial & Gastric Cancers
• Pancreatic, Prostate & Melanoma
• Rare syndromes like Li-Fraumeni, Cowden, and Peutz-Jeghers

Using advanced NGS technology, this saliva or blood-based test detects pathogenic variants (mutations) that significantly increase cancer risk so you can take preventive action before cancer develops.

With results in 14–21 days, Lab Tests Dubai provides comprehensive, science-backed insights helping oncologists, genetic counselors, and families make lifesaving decisions about screening, surgery, and lifestyle.

Available with private sample collection, this test ensures accuracy, confidentiality, and emotional support throughout your journey.

Why You Need This Test

If you’ve had cancer at a young age or have multiple relatives with cancer, this test could reveal an inherited mutation—so you can act now to reduce your risk and protect your loved ones.

You need the Hereditary Cancer Panel 57 if:

• You were diagnosed with breast cancer under 50 or ovarian cancer at any age
• You have two or more close relatives with breast, ovarian, colorectal, or pancreatic cancer
• A family member has tested positive for a BRCA or Lynch mutation
• You’ve had multiple primary cancers
• You’re considering risk-reducing surgeries (e.g., mastectomy, oophorectomy)
• You want personalized cancer prevention based on your DNA

This test helps:

• Identify high-risk mutations like BRCA1/2
• Guide enhanced screening (MRI, colonoscopy)
• Enable risk-reducing interventions (surgeries, medications)
• Inform family members of their potential risk
• Personalize treatment if cancer occurs

Knowledge power to prevent, not just react.

Who Should Consider This Test?

The Hereditary Cancer Panel 57 is recommended for:

• Individuals with Strong Family History of Cancer

Especially breast, ovarian, colorectal, pancreatic, or prostate.

• Early-Onset Cancer Survivors

Diagnosed under age 50.

• Those with Multiple Primary Cancers

e.g., breast and ovarian; colorectal and endometrial.

• Patients Preparing for Surgery or Treatment

To guide therapy (e.g., PARP inhibitors for BRCA+)

• People Considering Preventive Measures

Like prophylactic mastectomy or frequent colonoscopies.

• Relatives of Mutation Carriers

For cascade testing and early protection.

This test aligns with NCCN, ACMG, and ESMO guidelines and is increasingly considered standard of care in high-risk populations.

What Does the Test Reveal?

Using NGS with Sanger confirmation, the panel detects:

• 🔬 Pathogenic Variants – Known cancer-causing mutations
• 🔬 Likely Pathogenic Variants – Strong evidence of risk
• 🔬 Variants of Uncertain Significance (VUS) – Reviewed regularly as science evolves
• 🔬 Negative Result – No known mutation found (but risk may still exist)

Key Genes & Associated Risks

Results are interpreted using ACMG guidelines and literature-reviewed evidence (865+ genes reviewed).

What Happens If You Skip Genetic Testing?

Ignoring hereditary cancer risk can lead to:

• Late-Stage Diagnosis – due to lack of early screening
• Higher Mortality – from preventable cancers
• Missed Prevention Opportunities – like MRI screening or risk-reducing surgery
• Unaware Relatives – who may also carry the mutation
• Ineffective Treatment – without knowledge of targetable mutations

The good news? Most hereditary cancers are preventable with:

• Enhanced surveillance (annual MRI, colonoscopy)
• Risk-reducing surgeries (oophorectomy, mastectomy)
• Medications (tamoxifen, aspirin)
• Lifestyle changes (diet, exercise, smoking cessation)

Early testing longer, healthier life for you and your family.

How to Prepare for the Test

To ensure accurate results:

• No fasting required

• Continue regular medications

• Inform your doctor of:

• Personal cancer history

• Family tree with cancer diagnoses

• Prior genetic testing results

A simple sample is collected at home or in clinic then sent to our partner lab for analysis.

Test Overview: Hereditary Cancer Panel 57

Report Includes

• Variant classification (Pathogenic, VUS, Negative)
• Associated cancer risks
• NCCN guideline-based management recommendations
• Options for family testing (cascade screening)

Note: Not a diagnostic test for active cancer used for risk assessment only.

Benefits of the Hereditary Cancer Panel 57

• Detects Hidden Inherited Risk

Even without knowing family history.

• Guides Life-Saving Prevention

MRI, colonoscopy, surgery options.

• Empowers Family Awareness

Protect siblings, children, and cousins.

• Supports Precision Treatment

e.g., PARP inhibitors for BRCA+ cancers

• Peace of Mind

Know your risk—or rule it out.

If you’re worried about your family’s cancer history, the Hereditary Cancer Panel 57 gives you the answers you need in 14–21 days.